drugset / Trial / NCT00003003
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Phase 1
Completed
29 enrolled
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
Timeline
- Start
- 1996-09
- Primary completion
- 2000-08
- Completion
- 2000-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitomycin C | Other / unclassified | — | Intravenous |
| Subject | Mitoxantrone | Small molecule | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | Intravenous |